Good Response of a Salivary Duct Carcinoma to Androgen Deprivation Therapy.
10.3904/kjm.2016.90.4.357
- Author:
Jung Min LEE
1
;
Ji Ae LEE
;
Sang Youn LIM
;
Seong Min KIM
;
Yeon Ho LEE
;
Jin Gu YOON
;
Eun Joo KANG
Author Information
1. Division of Oncology and Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. kkangju11@naver.com
- Publication Type:Case Report
- Keywords:
Androgen receptor antagonist;
Salivary gland cancer;
Androgen receptors
- MeSH:
Aged;
Axilla;
Biopsy, Needle;
Chemoradiotherapy;
Cisplatin;
Drug Therapy;
Humans;
Leuprolide;
Lymph Nodes;
Male;
Neck;
Neck Dissection;
Neoplasm, Residual;
Parotid Gland;
Receptors, Androgen;
Recurrence;
Salivary Ducts*;
Salivary Gland Neoplasms;
Tomography, X-Ray Computed
- From:Korean Journal of Medicine
2016;90(4):357-360
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Salivary duct carcinoma (SDC) is a rare, aggressive tumor. Androgen deprivation therapy (ADT) has been shown to have beneficial effects on SDC-expressing androgen receptors (ARs). A 69-year-old male with a right neck mass presented to our clinic. Computed tomography (CT) of the neck revealed a mass (6 cm diameter) on the right parotid gland, and enlarged lymph nodes. Examination of a needle biopsy sample identified SDC-expressing ARs. We performed total parotidectomy with bilateral neck dissection and concurrent postoperative chemoradiotherapy (total 66 Gy) with cisplatin (35 mg/m2), followed by another two cycles of chemotherapy (cisplatin 60 mg/m2, 5 FU 750 mg/m2). Post-treatment neck CT indicated that no residual tumor tissue remained; however, chest CT indicated recurrence in the right axilla. We initiated ADT with bicalutamide and leuprolide. Five months later, the axillar tumor tissue had almost disappeared. Our case demonstrates that ADT is effective for SDC of ARs. Therefore, clinicians should consider ADT in recurrent or metastatic SDC of ARs.
